Teva (TEVA) Q2 2026 Earnings Call Transcript
Teva (TEVA) reported Q2 2026 revenue of $4.1B, down 1% year over year due to lower U.S. generic sales. Innovative brands rose, including AUSTEDO $696M (+40%), AJOVY $244M (+56%), and UZEDY $77M (+43%). Non-GAAP EPS was $0.02 and free cash flow was $622M (+31%). 2026 revenue guidance was raised to $16.5B-$16.85B; net debt was $12.9B (2.8x).
How this was made
The 30-second read
Why it matters
Traders can update models using the new 2026 revenue range, brand-level outlook increases, free cash flow improvement, and leverage metrics, while monitoring stated Q4 AUSTEDO YoY headwind from IRA-related purchasing patterns.
Market read
The combination of raised guidance, strong innovative-brand growth, and improved free cash flow is likely to be the primary driver for near-term positioning, tempered by generics weakness and IRA-related timing effects.
What to watch
The ADS-to-direct listing transition (Sept 2026) could create technical trading effects, and the Emalex acquisition accounting (in-process R&D) may complicate near-term comparability versus cash earnings.
Background
This is Teva’s Q2 2026 earnings call transcript with detailed segment performance, updated 2026 guidance, and pipeline/commercial outlooks for AUSTEDO, AJOVY, UZEDY, and biosimilars.
Ticker impact
Teva reported Q2 2026 revenue of $4.1B, guided 2026 revenue to $16.5B-$16.85B, and outlined AUSTEDO/AJOVY/UZEDY outlooks.
Bias toward upside on guidance credibility and innovative-brand momentum, with volatility around U.S. generics Revlimid weakness and expected Q4 AUSTEDO YoY decline.
The article contains multiple fresh, decision-relevant disclosures: quarterly results, updated 2026 guidance, brand outlook increases, FCF up 31%, net debt/EBITDA at 2.8x, and a stated plan to transition from ADS to direct NYSE listing in Sept 2026.
Market effects
Signals continued shift from generics to higher-margin innovative brands and biosimilars execution, relevant for large-cap pharma sentiment.
U.S. generics weakness (Revlimid) and IRA-driven purchasing normalization are specific to the U.S. market dynamics.
International brand momentum (AJOVY growth) and biosimilars pipeline progress support broader global specialty pharma risk appetite.
Counterpoint
The raised guidance may still mask underlying generics pressure (generic Revlimid down) and near-term AUSTEDO Q4 YoY decline tied to IRA-related purchasing changes.
Key entities
- companyTeva Pharmaceutical Industries Limited
Reported Q2 2026 results, updated 2026 guidance, and provided outlook for AUSTEDO, AJOVY, UZEDY, biosimilars, and pipeline milestones.
- acquisitionEmalex Biosciences
Acquisition cost of $726M recorded as in-process R&D during Q2, expanding Teva’s neuroscience pipeline.
- credit_rating_agencyFitch
Referenced investment-grade credit rating upgrade.
